Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · July 08, 2024

Outcomes of Combination Therapy With Pyrotinib, Trastuzumab, Palbociclib, and Fulvestrant in Patients With HR+/HER2+ Breast Cancer With Brain Metastasis

NPJ breast cancer

 

Additional Info

NPJ breast cancer
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis
NPJ Breast Cancer 2024 Jun 13;10(1)45, D Chen, F Xu, Y Lu, W Xia, C Du, D Xiong, D Song, Y Shi, Z Yuan, Q Zheng, K Jiang, X An, C Xue, J Huang, X Bi, M Chen, J Zhang, S Wang, R Hong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading